Submit Deal

FREENOME

Summary

Freenome is a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw.

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 139 M

Avg. Deal Size£ 70 M

Market Context

Senior Management

Gabe Otte
CEO
Mike Nolan
CEO
William Quirk
CFO

Sort

gabe otte

CEO at FREENOME

Manager

Deal

£ 126 M

Total Value

mike nolan

CEO at FREENOME

Manager

Deal

£ 13 M

Total Value

william quirk

CFO at FREENOME

Manager

Deal

£ 126 M

Total Value

sarah anderson

Senior Director at FREENOME

Manager

Deal

£ 13 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy